Fibrotic Interstitial Lung Disease
8
3
3
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
13%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
Efficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease
High Intensity Interval Training in Fibrotic Interstitial Lung Disease
Home-based Pulmonary Rehabilitation and Health Coaching in Fibrotic Interstitial Lung Disease
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease